TrialBreast cancer research and treatment2018

Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study.

Daneng Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.